Apitherapy is the medical use of honeybee products — venom, honey, pollen, propolis, royal jelly. In the context of Lyme disease, the focus is specifically on bee venom and its dominant peptide, melittin. The therapy is used either through direct bee stings applied to specific body points, or through injections of purified melittin or venom extract.
This page covers what is in venom that matters for Lyme, what the research shows, how the therapy is administered, and — critically — where the risk of a serious reaction lies.
What bee venom contains — and what each does
Bee venom is a complex mixture of peptides, enzymes, and small molecules. Not all are equally relevant to Lyme disease. The following are the components with documented biological activity relevant to this context.
A 26-amino-acid peptide that makes up approximately 50% of dry bee venom by weight. Melittin has a strong amphipathic structure — one end is attracted to water, the other to fats — which allows it to insert into and disrupt lipid membranes. This disruption mechanism is what makes it active against Borrelia in all its morphological forms, including the biofilm aggregates that protect the bacteria from antibiotics. It is the compound that most of the relevant Lyme research focuses on.
A small neurotoxic peptide (18 amino acids). At the doses delivered in therapeutic venom protocols, apamin stimulates adrenal cortex activity, increasing cortisol production. Because chronic Lyme is associated with HPA axis dysregulation and low cortisol in some patients, this effect is considered potentially beneficial — supporting the body's own anti-inflammatory capacity rather than suppressing inflammation pharmacologically.
An anti-inflammatory protein with prostaglandin-inhibiting properties, roughly comparable in mechanism to non-steroidal anti-inflammatory drugs. In Lyme disease, where much of the tissue damage and symptom burden is driven by the inflammatory response rather than direct bacterial damage, this component may contribute meaningfully to symptom relief beyond any direct antibacterial effect.
An enzyme that breaks down phospholipids — the building blocks of cell membranes. Works synergistically with melittin to disrupt bacterial membranes. PLA2 also activates the complement system, which is part of the innate immune response against pathogens.
What published studies show
The foundational study. Researchers tested whole Apis mellifera (honeybee) venom and isolated melittin against all three morphological forms of Borrelia burgdorferi: actively motile spirochetes, round-body persister forms, and biofilm-aggregated forms. The results were compared directly to the best-performing antibiotic combinations available — doxycycline, cefoperazone, and daptomycin, both individually and in combination.
Both whole venom and melittin alone showed activity against all three forms, including the biofilm aggregates that the antibiotic combinations could not eradicate. Melittin in particular showed superior activity to all tested antibiotic protocols against the biofilm form — the form most associated with treatment-resistant chronic infection. The study also used atomic force microscopy to visually document the membrane disruption caused by melittin.
A study examining BVT outcomes in 60 Lyme patients found that after one year of treatment at three sessions per week, 25% of patients either fully recovered or reached 85–95% improvement, reporting substantially increased energy and minimal remaining symptoms. The remaining patients reported varying degrees of partial improvement. This is a small study and not a randomised controlled trial, but it is clinical data from human patients — a step beyond the laboratory results above.
The laboratory evidence is genuinely strong for a non-pharmaceutical approach. Melittin's activity against Borrelia biofilm is particularly significant — this is the hardest form to treat and the one most associated with treatment failure. The clinical study is smaller and less controlled. Together they constitute a meaningful research base, not proof of clinical efficacy at the level required for mainstream adoption. No large randomised controlled trial has been conducted.
How bee venom therapy is administered
There are two main forms. Both deliver venom to the body; they differ in mechanism, dose control, and accessibility.
Bees — typically at the end of their natural life cycle — are applied directly to the skin at specific points, allowed to sting, and then removed. The venom sac continues to pump venom for several seconds after the sting; leaving the stinger in place briefly increases the dose delivered. Points are typically chosen to correspond to areas of symptom concentration or acupuncture-adjacent points along the spine, joints, and lymphatic pathways.
The advantage of live stings is that the full venom complex is delivered — all compounds together, as they exist naturally. The disadvantage is the pain, the need for a practitioner or a partner willing to manage live bees, and the complete inability to control dose precisely.
Commercially prepared bee venom extract is available as an injectable solution used by allergists for desensitisation therapy. Some integrative practitioners use this same preparation for therapeutic venom protocols, injecting small subcutaneous doses at specific points. This approach allows precise dose control, eliminates the need for live bees, and is more suitable for clinical settings. The trade-off is that isolated venom preparations may not contain the full range of compounds present in live venom at the same ratios.
Waking dormant Borrelia to expose it
One of the more unusual claims made by practitioners working with BVT is that melittin can draw dormant Borrelia forms out of sequestered tissue — bones, lymph nodes, the spinal column — and back into active circulation, where both the immune system and other treatments can reach it. The idea is that melittin disrupts the sheltered environment that allows Borrelia to persist in a dormant state.
If this mechanism operates as described, it would explain why some patients experience a significant worsening of symptoms — Herxheimer-like reactions — when beginning BVT, and why the clinical study required a full year of treatment to show durable results. The bacteria is not being killed instantly; it is being mobilised and then gradually eliminated as the immune system and venom interact with it over repeated sessions. Whether this mechanism is real in living tissue — rather than theorised from cell cultures — has not been formally established.
The risk that must come first
Bee venom is one of the most common triggers of severe anaphylaxis. Approximately 1–3% of the general population has an IgE-mediated allergy to bee venom that can cause systemic anaphylaxis — including airway constriction, cardiovascular collapse, and death — within minutes of exposure. This risk exists even in people with no known allergy to bees, and it can develop at any point, including after previously tolerating stings without reaction.
Any BVT protocol must have an epinephrine auto-injector (EpiPen) available at every session, in the hands of someone who can use it. This is not optional. Patients should not attempt BVT without emergency protocol in place. The first-sting allergy test must be performed at a location where emergency care is accessible — not remotely, not alone.
- Local reactions — pain, swelling, redness at the sting site are expected and normal. They typically subside within 24 hours. Significant swelling beyond the immediate sting area, or swelling that spreads rapidly, warrants stopping the session.
- Herxheimer reactions — as with other anti-Borrelia approaches, significant bacterial die-off can trigger worsening of Lyme symptoms in the days following treatment. This is typically worse in the early phases of a protocol. Hydration and rest support the body through this period.
- Cumulative sensitisation — repeated venom exposure can increase rather than decrease allergic sensitivity in some individuals. Allergy testing at intervals during a long protocol is advisable, not just at the outset.
- Venom quality variation — venom composition varies between individual bees, seasons, and geographic populations. Protocols using live bees have inherent dosing variability that commercial preparations reduce but do not eliminate entirely.
- Unsupervised protocols — some patients attempt BVT at home using purchased live bees. Without emergency protocol in place and without gradual dose titration under observation, this carries serious risk regardless of prior tolerance.
Other approaches in this section
Essential oils share a similar research profile with bee venom — strong in-vitro evidence against Borrelia persisters and biofilm, published in peer-reviewed journals, with the same gap to clinical human trials.
Healing mentality checkpoint
Bee venom therapy is one of the more demanding alternative approaches — physically, logistically, and emotionally. Three sessions a week for a year, each involving deliberate stings, requires a particular kind of sustained commitment. That commitment only makes sense if you go in understanding what the evidence does and does not say, and with the safety measures in place. Never start this protocol under pressure, in a hurry, or alone.
Read about healing mentality →Sources & further reading
- Socarras K.M. et al. — Antimicrobial activity of bee venom and melittin against Borrelia burgdorferi, Antibiotics (2017) — University of New Haven, PubMed PMID: 29186026
- Digitalshowcase.lynchburg.edu — Bee venom therapy for the treatment of Lyme disease: systematic review 2019–2024 (2025)
- Journal of Clinical and Cellular Immunology — clinical study of BVT in 60 Lyme patients
- Lyme Warrior — bee venom therapy protocol overview (lymewarrior.us)
- The Purist — patient account of apitherapy for Lyme disease (2019)
- ILADS clinical guidelines — ilads.org
Last updated: March 2026